{'52WeekChange': 1.0751879,
 'SandP52WeekChange': 0.0644362,
 'address1': '740 Heinz Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.85,
 'askSize': 2200,
 'averageDailyVolume10Day': 304187,
 'averageVolume': 589530,
 'averageVolume10days': 304187,
 'beta': 0.289075,
 'beta3Year': None,
 'bid': 2.76,
 'bidSize': 800,
 'bookValue': 0.738,
 'category': None,
 'circulatingSupply': None,
 'city': 'Berkeley',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.77,
 'dayLow': 2.64,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.793,
 'enterpriseToRevenue': 1.951,
 'enterpriseValue': 53213376,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 2.506,
 'fiftyTwoWeekHigh': 4.04,
 'fiftyTwoWeekLow': 0.901,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 46529022,
 'forwardEps': -0.9,
 'forwardPE': -3.0666668,
 'fromCurrency': None,
 'fullTimeEmployees': 96,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.29837,
 'heldPercentInstitutions': 0.44755,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aduro.com',
 'longBusinessSummary': 'Aduro Biotech, Inc., an immunotherapy company, '
                        'focuses on the discovery, development, and '
                        "commercialization of therapies to harness the body's "
                        'natural immune system for the treatment of patients '
                        'with challenging diseases. The company is developing '
                        'ADU-S100, which is in Phase I dose escalation '
                        'clinical trial and Phase Ib dose escalation clinical '
                        'trial in combination with spartalizumab to treat '
                        'patients with advanced, metastatic '
                        'treatment-refractory solid tumors; Phase I clinical '
                        'trial in combination with ipilimumab for the '
                        'treatment of relapsed and refractory melanoma; and '
                        'Phase II clinical trial in combination with '
                        'pembrolizumab, an approved anti-PD-1 antibody in '
                        'patients with squamous cell carcinoma of the head and '
                        'neck. It is also developing product candidates to '
                        'prevent or control immune responses through the '
                        'stimulator of interferon genes pathway. In addition, '
                        'the company is developing BION-1301, a fully blocking '
                        'humanized monoclonal anti-APRIL antibody that is in '
                        'Phase I clinical trial for IgA nephropathy; and CD27, '
                        'a co-stimulatory receptor, which is in preclinical '
                        'studies expressed on different immune cells, such as '
                        'T-lymphocytes and natural killer cells. It has '
                        'collaboration agreements with Novartis '
                        'Pharmaceuticals Corporation, Eli Lilly and Company, '
                        'and Merck Sharp and Dohme B.V.; and license '
                        'agreements with Karagen Pharmaceuticals, Inc., UC '
                        'Berkeley, and Memorial Sloan Kettering Cancer Center. '
                        'The company was formerly known as Oncologic, Inc. and '
                        'changed its name to Aduro Biotech, Inc. in June 2008. '
                        'Aduro Biotech, Inc. was founded in 2000 and is '
                        'headquartered in Berkeley, California.',
 'longName': 'Aduro Biotech, Inc.',
 'market': 'us_market',
 'marketCap': 223237072,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_2983625',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -66520000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.76,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.49,
 'phone': '510 848 4400',
 'previousClose': 2.775,
 'priceHint': 4,
 'priceToBook': 3.7398374,
 'priceToSalesTrailing12Months': 8.186178,
 'profitMargins': -2.43931,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.77,
 'regularMarketDayLow': 2.64,
 'regularMarketOpen': 2.76,
 'regularMarketPreviousClose': 2.775,
 'regularMarketPrice': 2.76,
 'regularMarketVolume': 265034,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 80883000,
 'sharesPercentSharesOut': 0.0402,
 'sharesShort': 3255381,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2918003,
 'shortName': 'Aduro Biotech, Inc.',
 'shortPercentOfFloat': 0.0495,
 'shortRatio': 3.69,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ADRO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.828,
 'twoHundredDayAverage': 2.61018,
 'volume': 265034,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aduro.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94710-2224'}